Plasminogen activator inhibitor 1 (PAI-1) is the main fibrinolysis inhibitor and high plasma levels are associated with an increased risk for vascular diseases. Inflammatory cytokines regulate PAI-1 through a hitherto unclear mechanism. Using reporter gene analysis we could identify a region in the PAI-1 promoter that contributes to basal expression as well as to TNF induction of PAI-1 in endothelial cells. Using this region as bait in a genetic screen we could identify Nur77 (NAK-1, TR3, NR4A1) as an inducible DNA-binding protein that binds specifically to the PAI-1 promoter. Nur77 drives transcription of PAI-1 through direct binding to a NGFI-B responsive element (NBRE) indicating monomeric binding and a ligand independent mechanism. Nur77 itself is transcriptionally upregulated by TNF . High expression levels of Nur77 and its co-localization with PAI-1 in atherosclerotic tissues indicate that the described mechanism for PAI-1 regulation may also be operative in vivo.
Introduction
Plasminogen activator inhibitor 1 (PAI-1) is the main inhibitor of tissue type (t-PA) and urokinase type (u-PA) plasminogen activators (reviewed in refs. 1, 2 ) . It functions as a serine protease inhibitor (SERPIN) by forming stable 1:1 stochiometric complexes 3 with its target proteases that are removed by scavenger receptors 4 . PAI-1 regulates intravascular fibrinolysis and tissue proteolysis and thereby controls thrombus dissolution as well as invasion and migration of cells through the extracellular matrix. PAI-1 is secreted by several tissues including the liver, adipose tissue, smooth muscle cells (SMC) and endothelial cells (EC), the latter ones producing low amounts of PAI-1 under normal, resting conditions. PAI-1 is present only in low concentrations (6 to 80 ng/ml) in normal human plasma. Elevated levels of plasma PAI-1 found in several pathologic
For personal use only. on August 16, 2017. by guest www.bloodjournal.org From 3 conditions are thought to increase the risk for vascular complications such as thrombosis 5, 6 or myocardial infarction 7 . Indeed, PAI-1 mRNA levels are increased in atherosclerotic vessels 8, 9, 10 . Such local upregulation of PAI-1 in vascular tissues might be caused by several mechanisms including hypoxia 11 , lipid mediators 12 , growth factors 13, 14 as well as inflammatory cytokines. Atherosclerosis is indeed regarded as a disease with a significant inflammatory component (reviewed in 15 ) and PAI-1 expression is upregulated by inflammatory mediators such as TNF 16 , IL-1 17; 18 or LPS 19 in human endothelial cells and in the model cell line HepG2 17,18; 20 . In fact, PAI-1 levels are increased during sepsis 21 where endothelial cells are a major source of this protein. Thus, PAI-1 is regarded as an "inflammatory response gene" that can alter the fibrinolytic potential of the vessel 22 and might lead to a thrombotic tendency.
The PAI-1 promoter has been analyzed for the presence of transcription factor consensus binding sites possibly responsible for its inducible expression: Best studied is the strong induction by TGF-mediated by binding of SMAD 3 and 4 proteins to consensus sites in the PAI-1 promoter 23 . SP1 elements in the proximal promoter region have been shown to mediate the response of PAI-1 to glucose 24 and angiotensin II 25 ; an AP -1 like binding site mediating the PAI-1 response to PKC and PKA signals 26, 27 ; a HRE (hypoxia response element) the binding of HIF-1 and the response to hypoxia 11 . The regulation of PAI-1 by inflammatory mediators is, however, still unclear. NF-B is the major transcription factor translocated to the nucleus in response to inflammatory stimuli where it drives directly transcription of responsive genes such as E-Selectin, VCAM-1, IL-8, tissue factor and others 18 . However, no NF-B binding site could be identified in the PAI-1 promoter.
Others and we have shown that the early growth response gene 1 (EGR-1) is another 31 ) were cultured as described 31, 32 .
Cells were used for experiments up to passage five. MCF-7 cells and JURKAT were cultured as recommended by ATCC (Manassas, VA).
Relative quantitative RT-PCR (Q -PCR):
RNA was isolated using Trizol (Invitrogen, Carlsbad, CA) reagent. 900ng of total RNA were reverse transcribed with MuLV-reverse transcriptase using the Gene Amp RNA PCR kit (Applied Biosystems, Foster City, CA) and oligo dT (16) primers. The mRNA sequences of the investigated genes were obtained from GenBank. The primers for -2 microglobulin were used as described by S. Wellman et al (ref. 33 ). The other primers were designed using the PRIMER3 software from the Nuclear run-on assay: Nuclear run-on assays were performed as described 35 . Nuclei were isolated from HUVEC that were either untreated or treated for 4h with 100U/ml TNF . The run on reaction contained 1.5x10 7 isolated nuclei and 250µCi of [ 32P] UTP for incorporation into the nascent pre-mRNA chains. 1µg of PAI-1 and GAPDH PCR product was applied to Hybond-N (Amersham Biosciences, Piscataway, NJ) nylon membranes using a slot blot apparatus followed by UV-crosslinking . The labeled RNA was isolated from the nuclei using Trizol reagent, washed and re-suspended in DEPC H 2 O. 1.5 million cpm of each labeled RNA were used for hybridization and the membranes were exposed on Phosphoimager plates (Amersham) for three days.
Electrophoretic Mobility Shift Assay: Electrophoretic mobility shift assays were performed as described 32 . Confluent HUVECs were stimulated with 100U/ml TNF for 2 hours. JURKAT were induced with PMA (10 ng/ml) and ionomycin (0.5 µg/ml) for 2 hours, controls with vehicle (1.1% DMSO). For the electrophoretic mobility shift assay 5 µg of nuclear extracts of HUVEC treated as indicated were incubated at room adding a 100-fold molar excess of unlabeled oligonucleotide to the reaction prior to the addition of the labeled probe. The samples were separated on a 5% polyacrylamide gel.
The gel was then dried and exposed to Phosphoimager plates (Amersham). Five colonies were clearly HIS-positive and 3 of these contained inserts coding for Nur77, the other two were false positives.
Transfection of HUVECs:
Fragments of the human PAI-1 promoter (deletion series from nt -1520 to -80 ending at +20 and a -850 construct with deletion of the bases from -250 to -270 [ NBRE] ) were cloned into a luciferase expression vector, pUBT-luc 36 .
Twenty-four hours before transfection, HUVEC were seeded in 6-well tissue-culture plates to reach 80% to 90% confluence the next morning. hours. Luciferase and beta-galactosidase assays were performed with cellular lysates of transfected cells as previously described 37 . All experimental values were determined from duplicate wells, and were performed at least twice.
The constructs for over-expression of Nur77 contained the coding sequence for amino acids 1 to 580 for the full length (wt) clone and 248 to 580 for the truncated (dominant negative) clone in the vector pCDNA3.1. The dominant negative construct for immunocytochemistry contained the coding sequence for amino acids 248 to 580 in the vector pEGFP-C1 (Clontech), resulting in a fusion protein with EGFP on its N-terminus.
As transfection control we used the empty pEGFP -C1. 
Results

TNF induces PAI-1 expression
To verify that TNF induces PAI-1 in endothelial cells, we followed PAI-1 expression in human umbilical vein endothelial cells (HUVECs) stimulated with TNF using relative quantitative RT-PCR (Q-PCR). PAI-1 mRNA levels increased already after one hour and reached 10-fold higher levels after four hours (Fig. 1a) . We performed nuclear run-on assays to assure that this induced mRNA increase is due to de novo synthesis. As shown in the insert to (Fig. 1b) .
For personal use only. on August 16, 2017. by guest www.bloodjournal.org From (Fig. 1c) . We therefore used this 20 bp stretch (Fig. 1d ) of the PAI-1 promoter as bait in a yeast one-hybrid screen employing an activated lymphocyte cDNA fusion library. We identified three positive clones, all of them containing the DNA binding domain of the orphan nuclear receptor Nur77.
Nur77 binds to a NBRE in the PAI-1 promoter
Upon analysis, we found that the PAI-1 promoter contains a putative NBRE (NGFI-B responsive element) from nt -261 to -254 also present in the oligonucleotides used for EMSA and in the bait sequence used for the yeast one-hybrid screen (Fig. 1d) . The NBRE is a well-described binding site for Nur77 monomers, and binding of Nur77 to this element has been shown to strongly activate transcription of other genes 39 , 40 .
To establish that Nur77 binds to that site in the PAI-1 promoter, we performed "supershift" assays after over-expressing a truncated Nur77 (aa 249-598, containing the Figure 2a shows increased specific binding to the labeled PAI-1 oligonucleotide (P) in transfected cells. This indicates that over-expression of Nur77 is sufficient to induce binding. Upon addition of an antibody recognizing Nur77, the specific bands were retarded in the gel, identifying the presence of Nur77 in the complex(es) bound to the labeled oligonucleotide (Fig.2a, lane 5) . The human T-cell leukemia cell line JURKAT is known to express significant levels of Nur77 only after stimulation 41 and indeed nuclear extracts of PMA and ionomycin stimulated JURKAT cells exhibited specific binding to the PAI-1 oligonucleotide (P, Fig. 2a, lane7 ) which was also "supershifted" by the anti Nur77 antibody (Fig. 2a, lanes 8 In order to analyze whether binding of Nur77 to the NBRE in the PAI-1 promoter involves interaction with the 5' adenines, we designed an oligonucleotide where the 
DNA and ligand binding domains) in MCF-7 cells, which express low endogenous
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original site in the PAI-1 promoter was changed from 5'-GAAAGGTCA-3' (PAI-NBRE) to 5'-GACAGGTCA-3' (PAI-A11C, A, see Fig.1d ). This mutation strongly reduced binding of Nur77 to the oligonucleotide ( Fig.2b; lane 8) . Taken together these data indicate that the PAI-1 promoter contains a NBRE site that is a target for monomeric binding of Nur77 and that Nur77 by itself is sufficient to induce specific binding. 4) and addition of the E20 antibody, which recognizes the C-terminus of the Nur77 family of proteins (lane 5). JURKAT cells were induced with ionomycin and PMA and incubated with a radio-labeled NBRE found in the PAI-1 promoter (P, lanes 6-10) and a canonical consensus NBRE (N, lanes 11-14) . The extracts were also incubated with E20 antibody (lanes 8 and 13) . Binding was competed with a 100-fold molar excess of unlabeled oligonucleotides as indicated (PAI -NBRE, P;
Con. NBRE, N). Specific binding activity of nuclear protein complexes is indicated by black arrows. A supershift resulting from binding of the Nur77 antibody is indicated by white arrows.
b, HUVECs were stimulated with TNF and nuclear extracts were incubated with radioactively labeled oligonucleotides containing the NBRE of the PAI-1 promoter (P).
The same extracts were incubated with radioactively labeled oligonucleotides containing the NBRE of the PAI-1 promoter that were mutated in the positions indicated in Fig 1d (PAI-T15A, T; PAI-A11C, A). Specific binding activity of nuclear protein complexes is indicated by black arrows
TNF , LPS and IL-1 induce expression of Nur77
The specific binding activity to the PAI-1 oligonucleotide was strongly increased when nuclear extracts from TNF stimulated cells were used, indicating regulation of Nur77 by TNF ( Fig. 2b; lane3) ; such increased binding activity resembles the results seen in Fig.   2 a(lane3) , when Nur77 was overexpressed. To assess whether in fact TNF regulates Nur77 at the level of expression, we followed Nur77 mRNA levels by Q-PCR. TNF induced a rapid burst of Nur77 detectable already after 30 minutes that peaked after one hour of stimulation and declined to unstimulated levels after four hours (Fig. 3a) ; this change in Nur77 mRNA was followed by an increase in Nur77 protein (insert Fig. 3a) . PAI-1 mRNA levels increased with a delay and then continued to rise steadily until four hours after stimulation as already shown in Fig.   1a . Immunofluorescence data of corresponding experiments in cultured cells are shown in To test whether other inflammatory mediators also regulate Nur77 and PAI-1 in a similar way, we performed experiments as shown in Fig.3a using LPS (Lipopolysaccharide) or IL-1 (Interleukin 1). As shown in Fig. 3c , IL-1 induced upregulation of Nur77 and PAI-1 mRNA in a comparable way. This indicates that Nur77-mediated PAI-1 regulation might not be restricted to TNF . Also LPS induced upregulation of Nur77 and PAI -1; however, the different time course seen in response to LPS indicates overall differences in the signal transduction pathway between LPS and Il-1 or TNF , respectively. Such different kinetics of the induction of inflammatory response genes have been described already previously 45 . The early increase in PA1-1 mRNA further indicates addition regulatory mechanism including changes in mRNA stability as indicated by previous studies 46 .
For 
TNF induction of PAI-1 depends on Nur77 and the presence of the NBRE in the PAI-1 promoter
To prove that increased expression of Nur77 directly activates the PAI-1 promoter, we performed reporter gene assays. PAI-1 reporter constructs containing the NBRE of the PAI-1 promoter were strongly induced when Nur77 was co-expressed (Fig.4a) , whereas PAI-1 promoter constructs with a NBRE deletion did not respond to Nur77 overexpression (not shown) or to TNF (Fig. 4a) . Consistently, over-expression of Nur77 as well as TNF stimulation strongly induced a 4xNBRE luciferase reporter gene construct (Fig. 4b) . Co -expression of a dominant negative mutant 42 of Nur77 (dnNur77) reduced basal reporter gene activity and completely abolished the upregulation of the reporter gene by TNF (Fig. 4a) . When a dnNur77 fused to EGFP (dnNur77-EGFP) was showed no expression of PAI-1.
Nur77 is present in atherosclerotic vessels and co-localizes with PAI-1
Having shown that TNF upregulates Nur77 and in turn PAI-1 expression in ECs, we were interested to see whether Nur77 is also upregulated in atherosclerotic vessels in vivo. When normal or atherosclerotic coronary arteries were stained for Nur77 and PAI-1, a strong Nur77 signal was seen only in the plaque area (in SMCs, macrophages and ECs -stained with antibodies against CD-31, Fig. 5g , of the neointima and vessels of the adventitia). In these areas, PAI-1 staining co-localized with Nur77 staining (Fig. 5a-j) .
PAI-1 was additionally seen in the extracellular matrix especially of the plaque (Fig. 5d and 5f). Nur77 was also strongly upregulated in the neointima (Fig.5l) while in the media only a scattered staining in SMCs was seen (Fig. 5m) . This pattern of Nur77 staining is consistent with a model in which inflammatory cells in the neointima release inflammatory cytokines, which in turn induces Nur77 in SMC of the neointima and the e-g, Co-immunostaining of Nur77 and PAI-1 in a human atherosclerotic lesion. The vessel was stained for Nur77 (green, e) or PAI-1 (red, f) or CD31 (blue, g). h-j, Endothelial cells of vasa vasora in human atherosclerotic coronary arteries express both Nur77 (h) and PAI-1 (j) which co-localize (i).
k-m, Expression of Nur77 in a human atherosclerotic vessel (k) with higher expression in the neointima (l) and lower expression in the media (m) .
Discussion
Upregulation of PAI-1 during inflammation is known since long and in fact, the deleterious outcome of sepsis was for some time thought to be caused by the extremely high levels of PAI-1 found under these conditions 48 . However, the PAI-1 promoter is lacking consensus sequences for the inflammatory transcription factor NF-B 49 Our data demonstrating that Nur77 expression is increased in atherosclerotic vessels and co-localizes there with PAI-1 indicate the importance of this mechanism also in vivo.
For personal use only. on August 16, 2017. by guest www.bloodjournal.org From Recent work by deVries et al 53 , who showed that Nur77 is found induced in a screen for genes upregulated by pro-atherogenic cytokines in smooth muscle cells, supports our finding, as well as a report by Arkenbout et al. 54 , demonstrating the involvement of the nuclear receptor subfamily 4 in neointima formation in a mouse model. Nur77 (NAK-1, TR3) is a member of this nuclear receptor subfamily and the human homolog 55; 56 of mouse Nur77 and rat NGFI-B. Nur77 was shown to be involved in T-cell receptor induced apoptosis 42; 57 , and to be induced during B-cell differentiation 58 , in response to growth factors 59 , to mechanical stress 60 and to dietary fatty acids 61 . We here show for the first time that the transcription factor Nur77 is part of the TNF response and mediates TNF induced PAI-1 upregulation.
In conclusion, we have delineated the mechanism by which TNF induces PAI-1 expression in endothelial cells and identified Nur77 as the responsible transcription factor. Increased expression of Nur77 and PAI-1 in vascular cells of atherosclerotic tissues indicates that Nur77 might be a pivotal response gene for inflamed vascular cells and a possible target for therapeutic intervention.
